NasdaqGM - Nasdaq Real Time Price ? USD Alvotech (ALVO) Follow Compare 12.40 +0.15 (+1.22%) As of 11:00 AM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI? (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara? (ustekinumab) Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024SELARSDI’s U.S. launch for all indications is expected in Q1 2025 REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U GlobeNewswire ? 4 hours ago ALVO +1.22% ALVOW European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia? and Xgeva? Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia? and Xgeva? (denosumab). “EMA acceptance marks an important step towards making AVT03 available to patients and caregivers in Europe,” said Joseph McClellan, Chief Scientific Officer of Alvotec GlobeNewswire ? 12 days ago ALVO +1.22% ALVOW High Growth Tech Stocks in the United States to Watch In the last week, the market has stayed flat while the Materials sector gained 3.1%, and over the past 12 months, it has risen by 32% with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks becomes crucial as they often offer significant potential for capital appreciation in a steadily advancing market. Simply Wall St. ? 25 days ago ALVO +1.22% ALVOW FIVN Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio? Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio?Sales of Entyvio (vedolizumab) were about $5.4 billion globally in the last 12 months up to June 30, 2024 Entyvio is indicated for the treatment of Ulcerative Colitis and Crohn’s disease Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the GlobeNewswire ? 27 days ago ALVO +1.22% ALVOW Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Members of the management team will hold an in-person fireside chat on September 5, 2024, starting at 5:35 pm EDT (21:35 GMT). A live audio webcast of the fireside chat will be available and can be accessed either during or after the event in the even GlobeNewswire ? last month ALVO +1.22% ALVOW Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023) Alvotech ( NASDAQ:ALVO ) Second Quarter 2024 Results Key Financial Results Revenue: US$198.8m (up by US$194.3m from 2Q... Simply Wall St. ? 2 months ago ALVO +1.22% ALVOW Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week Key Insights The considerable ownership by private equity firms in Alvotech indicates that they collectively have a... Simply Wall St. ? 2 months ago ALVO +1.22% ALVOW Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190% increase from the same period last year, with Q2 product revenues contributing $53 millionLicense and other revenues for the first six months increased to $170 million, with Q2 license and other revenues contributing $145 millionAdjusted EBITDA in the first six months was $64 million, compared to negati GlobeNewswire ? 2 months ago ALVO +1.22% ALVOW European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea? (aflibercept) The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA GlobeNewswire ? 2 months ago ALVO +1.22% ALVOW Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET REYKJAVIK, Iceland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the year ended June 30, 2024, after U.S. markets close on Thursday, August 15, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Friday August 16, 2024, at 8:00 am EDT (12 noon GMT GlobeNewswire ? 2 months ago ALVO +1.22% ALVOW STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology1, dermatology and rheumatologyCreates competition at earliest opportunity, enabling straightforward switching to broaden patient access and control costs in a growing market, with accessible indications currently estimated at approxi GlobeNewswire ? 2 months ago ALVO +1.22% ALVOW Alvotech Announces Closing of Private Debt Financing REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”). The closing has allowed Alvotech to refinance outstanding debt obligations, reduce the cost of capital and improve its overall debt maturity profile. Following the closing of the Fa GlobeNewswire ? 3 months ago ALVO +1.22% ALVOW Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia? and Xgeva? Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia? (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endpointAlvotech expects to file marketing applications for AVT03 later this year for major global markets Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines f GlobeNewswire ? 3 months ago ALVO +1.22% ALVOW Alvotech Issues New Shares to Holders of Convertible Bonds REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, with maturity on December 20, 2025 (the “Convertible Bonds”). Today, Alvotech issued 22,073,578 new ordinary shares in exchange for Convertible Bonds, at t GlobeNewswire ? 3 months ago ALVO +1.22% ALVOW Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows: Strong preliminary revenue growth with total revenues for the second quarter between $196 - $201 million. Preliminary total revenues for the first six month GlobeNewswire ? 3 months ago ALVO +1.22% ALVOW Alvotech Receives Conversion Notices for Majority of Convertible Bonds REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, respectively, with maturity on December 20, 2025 (the “Convertible Bonds”) have elected to convert the principal and accrued interest into ordin GlobeNewswire ? 3 months ago ALVO +1.22% ALVOW Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea? LD/HD in Europe Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea? in Europe Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient access REYKJAVIK, Iceland and LONDON, June 18, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK GlobeNewswire ? 4 months ago ALVO +1.22% ALVOW Alvotech and STADA add to Strategic Alliance through Denosumab Partnership STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia?/Xgeva? (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle EastThis partnership for the osteoporosis and cancer-related molecule builds on the two company’s existing strategic alliance in Europe. The first product launched through the alliance was Hukyndra?, a high-concentration biosimilar to Humira? (adalimumab) Extended alliance comes GlobeNewswire ? 4 months ago ALVO +1.22% ALVOW Alvotech Announces Strategic Refinancing Agreement Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a strategic refinancing transaction. The financing, led by GoldenTree Asset Management, with participation from other institutional investors (collectively, the “Lenders”), will enable Alvotech (the “Company”) to improve cost of capital, address upcoming debt maturities in 2025 and enhance its financial fle GlobeNewswire ? 4 months ago ALVO +1.22% ALVOW Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Healthcare Conference in New York on June 5-6, 2024. Alvotech will present and host investor and business meetings at the conference. Anil Okay, Chief Business Officer, is scheduled to give a presentation at the conference on June 6, 2024, at 1:00 pm GlobeNewswire ? 4 months ago ALVO +1.22% ALVOW Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ALVO S&P 500 YTD +8.01% +22.41% 1-Year +42.86% +38.22% 3-Year +30.53% +59.24%
